MR13A9

DRUG2 trials

Sponsors

Kissei Pharmaceutical Co., Ltd.

Conditions

Uremic Pruritus

Phase 2

A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

CompletedNCT03802617

Kissei Pharmaceutical Co., Ltd.Uremic Pruritus

Start: 2019-02-01End: 2019-10-22Updated: 2025-12-05

Phase 3

A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

CompletedNCT04711603

Kissei Pharmaceutical Co., Ltd.Uremic Pruritus

Start: 2021-01-16End: 2022-09-26Updated: 2025-09-10

Related Papers

Long-term efficacy and safety of difelikefalin in moderate-to-severe pruritus in Japanese hemodialysis patients: a 52-week open-label extension period of a phase 3 trial

Renal Replacement Therapy2024-07-193 citations

Difelikefalin for Hemodialysis Patients with Pruritus in Japan

NEJM Evidence2023-10-1713 citations

Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis

JAMA Network Open2022-05-0534 citations